ClinicalTrials.gg
CompletedNCT04129398Updated Aug 21, 2024Results posted

MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

A Phase 3 interventional study of Letermovir tablet and Letermovir IV in Cytomegalovirus Infection and Cytomegalovirus Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Enrollment
13th of 17
22 · median 80
Started
2019
with 3 others
Phase 3
6 of 17
3 open now
Registered
4th of 17
by date
Lead sponsor
4 of 17
Merck Sharp & Dohme LLC

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 13th largest by enrollment, is one of 4 that started in 2019, is one of 6 in phase 3, and was the 4th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.

03

Conditions studied

  • Cytomegalovirus Infection
  • Cytomegalovirus Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets recipient and/or donor CMV Immunoglobulin G (IgG) serostatus.
  • Anticipates receiving a primary or secondary allograft kidney at the time of screening and have received a primary or secondary allograft kidney at the time of allocation.
  • Is within 0 (i.e., day of transplantation) to 7 days (inclusive) post-kidney transplant at the time of allocation.
  • Is a Japanese male or female from 18 years to any years of age inclusive, at the time of signing the .
  • Female is not pregnant or breastfeeding, and is not a woman of (WOCBP); but if a WOCBP, she is using an acceptable method, or is abstinent from heterosexual intercourse, and must have a negative highly sensitive pregnancy test within 72 hours before the first dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Has received a previous solid organ transplant or hematopoietic stem cell transplant ().
  • Is a multi-organ transplant recipient (e.g., kidney-pancreas).
  • Has a history of CMV disease or suspected CMV disease within 6 months prior to allocation.
  • Has positive results on CMV assay and/or CMV antigen test at any time between the completion of the transplant surgery and time of allocation.
  • Has suspected or known to active or inactive ingredients of LET formulations.
  • Is on dialysis (for the purposes of this protocol dialysis includes hemofiltration) or plasmapheresis at the time of allocation.
  • Has Class C severe hepatic insufficiency at screening.
  • Has post-transplant renal function of (CrCl) ≤10 mL/min at allocation (measured locally).
  • Has both moderate hepatic insufficiency AND moderate-to-severe renal insufficiency at screening.
  • Has any uncontrolled infection on the day of allocation.
  • Has documented positive results for antibody (HIV-Ab) test at any time prior to allocation, or for virus antibody (HCV-Ab) and with detectable HCV RNA within 90 days prior to allocation or surface antigen (HBsAg) within 90 days prior to allocation.
  • Requires mechanical ventilation, or is hemodynamically unstable, at the time of allocation.
  • Has a history of ≤5 years prior to signing .
  • Has received within 30 days prior to allocation or plans to receive during the study any of the following: CMV immune globulin; any CMV antiviral agent/biologic therapy.
  • Has received any dose of LET prior to allocation.
  • Has received within 7 days prior to allocation or plans to receive during the study any anti-CMV drug therapy.
  • Is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.
  • Is taking or plans to take any of the prohibited medications listed in the protocol.
  • Is currently participating or has participated in a study with an unapproved investigational compound or device within 28 days, or 5× half-life of the investigational compound.
  • Has previously participated in this study or any other study involving LET.
  • Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study.
  • Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through at least 28 days following cessation of study therapy.
  • Is expecting to donate eggs starting from the time of consent through at least 28 days following cessation of study therapy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Letermovir

    Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 28 weeks, beginning up to 7 days post-transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A (CsA) and 480 mg once daily for participants not receiving CsA. IV infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.

    Drug: Letermovir tablet · Drug: Letermovir IV

Interventions

  • A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks

    Also known as: MK-8228, PREVYMIS®

  • IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks

    Also known as: MK-8228, PREVYMIS®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Percentage of participants with one or more adverse events (AEs)

    Time frame: Up to week 52 post-transplant

  2. Percentage of Participants Who Discontinued From Study Drug Due to an AE

    Percentage of participants who discontinued from study drug due to an AE

    Time frame: Up to week 28 post-transplant

Secondary outcomes

  1. Percentage of Participants With Adjudicated CMV Disease or Undergone Anti-CMV Treatment

    CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Participants who have undergone anti-CMV treatment was defined as initiation of approved anti-CMV agents based on at least one positive cell on CMV antigenemia and/or quantifiable CMV DNA PCR assay performed locally.

    Time frame: Up to Week 52 post-transplant

  2. Percentage of Participants With Adjudicated CMV Disease

    CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included.

    Time frame: Up to Week 52 post-transplant

  3. Percentage of Participants With Quantifiable CMV DNAemia

    Quantifiable CMV DNAemia (central) was defined as any case with a numeric value or \>910,000,000 (not including reporting of PCR results as "detected, not quantifiable") using the Roche COBAS® AmpliPrep/COBAS TaqMan® (CAP/CTM) assay, which was performed by the central laboratory.

    Time frame: Up to Week 52 post-transplant

  4. Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir-oral Treatment

    AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an oral administration of letermovir.

    Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

  5. Trough Concentration (Ctrough) of Plasma Letermovir - Oral Treatment

    Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an oral administration of letermovir.

    Time frame: Any day between Days 6-10: 24hrs post-dose

  6. Maximum Concentration (Cmax) of Plasma Letermovir - Oral Treatment

    Cmax was defined as the maximum concentration of letermovir observed in plasma following an oral administration of letermovir.

    Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

  7. Time to Reach Cmax (Tmax) of Plasma Letermovir - Oral Treatment

    Tmax was defined as the time required post dosing to reach a maximum plasma concentration of letermovir following an oral administration of letermovir.

    Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

  8. Apparent Clearance at Steady State (CLss/F) of Plasma Letermovir - Oral Treatment

    Apparent clearance at steady state (CLss/F) of plasma letermovir following an oral administration of letermovir.

    Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

  9. Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir - IV Treatment

    AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an IV administration of letermovir was intended to measure.

    Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

  10. Trough Concentration (Ctrough) of Plasma Letermovir - IV Treatment

    Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an IV administration of letermovir was intended to measure.

    Time frame: Pre-dose on Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 and 28

  11. Concentration at the End of Infusion (Ceoi) of Plasma Letermovir - IV Treatment

    Ceoi is defined as the amount of letermovir in plasma following an IV administration of letermovir was intended to measure.

    Time frame: Any day between Days 6-10: at end of infusion (1 hours post dose)

  12. Clearance at Steady State (CLss) of Plasma Letermovir - IV Treatment

    Clearance at steady state (CLss) of plasma letermovir following an IV administration of letermovir was intended to measure.

    Time frame: Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

07

Results

Posted Apr 1, 2024

Participant flow

This study enrolled adult Japanese kidney transplant recipients who are organ donor (D) or organ recipient (R) seropositive (D+/R-, D+/R+ or D-/R+) for Cytomegalovirus (CMV) as participants.

Participant flow — Overall Study
MilestoneLetermovir
Started22
Completed20
Not completed2
Withdrew: Physician decision2

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs)

Percentage of participants with one or more adverse events (AEs)

Time frame:
Up to week 52 post-transplant
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsLetermovir
Percentage of Participants With Adverse Events (AEs)90.9
PrimaryPercentage of Participants Who Discontinued From Study Drug Due to an AE

Percentage of participants who discontinued from study drug due to an AE

Time frame:
Up to week 28 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued From Study Drug Due to an AE
Percentage of participantsLetermovir
Percentage of Participants Who Discontinued From Study Drug Due to an AE13.6
SecondaryPercentage of Participants With Adjudicated CMV Disease or Undergone Anti-CMV Treatment

CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included. Participants who have undergone anti-CMV treatment was defined as initiation of approved anti-CMV agents based on at least one positive cell on CMV antigenemia and/or quantifiable CMV DNA PCR assay performed locally.

Time frame:
Up to Week 52 post-transplant
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adjudicated CMV Disease or Undergone Anti-CMV Treatment
Percentage of ParticipantsLetermovirLetermovir D+/R-Letermovir R+
With CMV Disease or Started Anti-CMV Treatment Through Week 28 Post-Transplant0.0 (0.0 to 16.1)0.0 (0.0 to 26.5)0.0 (0.0 to 33.6)
With CMV Disease or Started Anti-CMV Treatment Through Week 52 Post-Transplant19.0 (5.4 to 41.9)33.3 (9.9 to 65.1)0.0 (0.0 to 33.6)
SecondaryPercentage of Participants With Adjudicated CMV Disease

CMV disease was defined as the presence of either CMV end-organ disease or CMV syndrome and was confirmed by an independent, blinded Clinical Adjudication Committee (CAC). Only CAC-confirmed ("adjudicated") cases were included in percentage of participants who met the endpoint. Investigator-assessed cases which were not confirmed by the CAC were not included.

Time frame:
Up to Week 52 post-transplant
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adjudicated CMV Disease
Percentage of ParticipantsLetermovirLetermovir D+/R-Letermovir R+
With CMV Disease Through Week 28 Post-Transplant0.0 (0.0 to 16.1)0.0 (0.0 to 26.5)0.0 (0.0 to 33.6)
With CMV Disease Through Week 52 Post-Transplant9.5 (1.2 to 30.4)16.7 (2.1 to 48.4)0.0 (0.0 to 33.6)
SecondaryPercentage of Participants With Quantifiable CMV DNAemia

Quantifiable CMV DNAemia (central) was defined as any case with a numeric value or \>910,000,000 (not including reporting of PCR results as "detected, not quantifiable") using the Roche COBAS® AmpliPrep/COBAS TaqMan® (CAP/CTM) assay, which was performed by the central laboratory.

Time frame:
Up to Week 52 post-transplant
Reported as:
Number · Percentage of participants
Percentage of Participants With Quantifiable CMV DNAemia
Percentage of participantsLetermovirLetermovir D+/R-Letermovir R+
Quantifiable CMV DNAemia Through Week 28 Post-transplant4.8 (0.1 to 23.8)8.3 (0.2 to 38.5)0.0 (0.0 to 33.6)
Quantifiable CMV DNAemia Through Week 52 Post-transplant23.8 (8.2 to 47.2)41.7 (15.2 to 72.3)0.0 (0.0 to 33.6)
SecondaryArea Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir-oral Treatment

AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an oral administration of letermovir.

Time frame:
Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir-oral Treatment
ng*hr/mLLetermovir
Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir-oral Treatment156000 ± 47.3
SecondaryTrough Concentration (Ctrough) of Plasma Letermovir - Oral Treatment

Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an oral administration of letermovir.

Time frame:
Any day between Days 6-10: 24hrs post-dose
Reported as:
Geometric mean · ng/mL
Trough Concentration (Ctrough) of Plasma Letermovir - Oral Treatment
ng/mLLetermovir
Trough Concentration (Ctrough) of Plasma Letermovir - Oral Treatment1700 ± 121.9
SecondaryMaximum Concentration (Cmax) of Plasma Letermovir - Oral Treatment

Cmax was defined as the maximum concentration of letermovir observed in plasma following an oral administration of letermovir.

Time frame:
Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of Plasma Letermovir - Oral Treatment
ng/mLLetermovir
Maximum Concentration (Cmax) of Plasma Letermovir - Oral Treatment17900 ± 31.1
SecondaryTime to Reach Cmax (Tmax) of Plasma Letermovir - Oral Treatment

Tmax was defined as the time required post dosing to reach a maximum plasma concentration of letermovir following an oral administration of letermovir.

Time frame:
Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Reported as:
Median · hr
Time to Reach Cmax (Tmax) of Plasma Letermovir - Oral Treatment
hrLetermovir
Time to Reach Cmax (Tmax) of Plasma Letermovir - Oral Treatment2.50 (0.92 to 23.35)
SecondaryApparent Clearance at Steady State (CLss/F) of Plasma Letermovir - Oral Treatment

Apparent clearance at steady state (CLss/F) of plasma letermovir following an oral administration of letermovir.

Time frame:
Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose
Reported as:
Geometric mean · L/hr
Apparent Clearance at Steady State (CLss/F) of Plasma Letermovir - Oral Treatment
L/hrLetermovir
Apparent Clearance at Steady State (CLss/F) of Plasma Letermovir - Oral Treatment3.08 ± 47.3
SecondaryArea Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Plasma Letermovir - IV Treatment

AUCtau was defined as a measure of letermovir exposure that was calculated as the product of plasma drug concentration and time following an IV administration of letermovir was intended to measure.

Time frame:
Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

No measurements were reported for this outcome.

SecondaryTrough Concentration (Ctrough) of Plasma Letermovir - IV Treatment

Ctrough was defined as the minimum concentration of letermovir that occurred immediately following an IV administration of letermovir was intended to measure.

Time frame:
Pre-dose on Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 and 28

No measurements were reported for this outcome.

SecondaryConcentration at the End of Infusion (Ceoi) of Plasma Letermovir - IV Treatment

Ceoi is defined as the amount of letermovir in plasma following an IV administration of letermovir was intended to measure.

Time frame:
Any day between Days 6-10: at end of infusion (1 hours post dose)

No measurements were reported for this outcome.

SecondaryClearance at Steady State (CLss) of Plasma Letermovir - IV Treatment

Clearance at steady state (CLss) of plasma letermovir following an IV administration of letermovir was intended to measure.

Time frame:
Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose

No measurements were reported for this outcome.

Adverse events

Collected over Up to week 52 post-transplant. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letermovir0/22 (0%)7/22 (31.8%)13/22 (59.1%)
Most frequent serious events
Most frequent serious events
EventLetermovir
ConstipationGastrointestinal disorders1/22
Adenoviral haemorrhagic cystitisInfections and infestations1/22
Herpes zosterInfections and infestations1/22
Pneumocystis jirovecii pneumoniaInfections and infestations1/22
TonsillitisInfections and infestations1/22
Urinary tract infectionInfections and infestations1/22
Complications of transplanted kidneyInjury, poisoning and procedural complications1/22
LymphoceleVascular disorders1/22
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLetermovir
StomatitisGastrointestinal disorders4/22
DiarrhoeaGastrointestinal disorders3/22
Neutrophil count decreasedInvestigations3/22
HyperlipidaemiaMetabolism and nutrition disorders3/22
AnaemiaBlood and lymphatic system disorders2/22
LeukopeniaBlood and lymphatic system disorders2/22
NauseaGastrointestinal disorders2/22
Urinary tract infectionInfections and infestations2/22
Incisional herniaInjury, poisoning and procedural complications2/22
InsomniaPsychiatric disorders2/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Letermovir
Mean48.5 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Letermovir
Female6
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Letermovir
Hispanic or Latino0
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Letermovir
American Indian or Alaska Native0
Asian22
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital ( Site 0002)
    Nagoya, Aichi 466-8650, Japan
  • Sapporo City General Hospital ( Site 0004)
    Sapporo, Hokkaido 060-8604, Japan
  • Osaka University Hospital ( Site 0003)
    Suita, Osaka 565-0871, Japan
  • Tokyo Women's Medical University Hospital ( Site 0001)
    Tokyo, 162-8666, Japan
09

References and documents

Publications

  • Ishida H, Goto N, Imamura R, Sasaki H, Unagami K, Futamura K, Murata Y, Oshima N, Eto T, Haber B. Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study. Clin Exp Nephrol. 2024 Aug;28(8):822-831. doi: 10.1007/s10157-024-02471-0. Epub 2024 Apr 13. PubMed 38615067 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Oct 2022, 33 months.

Results were first posted in Apr 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2019
First posted
Oct 16, 2019
StartActual
Dec 27, 2019
Primary completionActual
Oct 6, 2022
CompletionActual
Oct 6, 2022
Results first posted
Apr 1, 2024
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04129398
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Dec 27, 2019
Primary completion
Oct 6, 2022
Completion
Oct 6, 2022
Results posted
Apr 1, 2024
Last update
Aug 21, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion